Porphyria cutanea tarda in the Basque Country: significance of HFE gene mutations and of external factors.

Castiella A, Zapata E, Otazua P, Zubiaurre L.

Liver Int. 2012; 32: 1597-1600. FI: 3.824 (Q1).

Osseous metaplasia in a gastric adenomatous polyp

Zapata E, Castiella A, Zubiaurre L, Agirre A, Rodríguez J.

Endoscopy. 2012; 44: 81-90. FI: 5.210 (Q1).

Representacion Grp HEBRA. Screening practices for hepatitis B virus prior to viral reactivation risk therapies among different medical specialties.

García-Bengoechea M, Hernández-López C, Crespo J, Gea F.

HEBRA Project. Med. Clin. 2012; 139: 498-501. FI: 1.385 (Q2).

Effect of Neoadjuvant Chemotherapy in Hepatic Steatosis.

Jiménez R, Hijona E, Emparanza J, Alustiza JM, Hijona L, Macarulla MT, Portillo MP, Herreros-Villanueva M, Beguiristain A, Arenas J, Bujanda L.

Chemotherapy. 2012; 58: 89-94. FI: 1.816 (Q3).

ORIENTE Study Grp. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.

Buti M, Morillas RM, Prieto M, Diago M, Perez J, Sola R, Bonet L, Palau A, Testillano M, García-Samaniego, J, Rodríguez M.

Eur. J. Gastroenterol. Hepatol. 2012; 24: 535-542. FI: 1.757 (Q3).

Epidermal Growth Factor Receptor Signaling in Hepatocellular Carcinoma: Inflammatory Activation and a New Intracellular Regulatory Mechanism

Berasain C, Nicou A, García-Irigoyen O, Ujue Latasa M, Urtasun R, Elizalde M, Salis F, Perugorria MJ, Prieto J, Recio JA, Corrales FJ, Avila MA.

Dig. Dis. 2012; 30: 524-531. FI: 2.373 (Q3).

Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation.

Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, Robinson S, White SA, Burt AD, Oakley F, Tsukamoto H, Mann DA, Mann J.

Hepatology. 2012; 56: 1129-1139. FI: 11.665 (Q1).

Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.

Masyuk TV, Radtke BN, Stroope AJ, Bañales JM, Masyuk AI, Gradilone SA, Gajdos G, Bedekovicsne CN, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso, NF.

Gastroenterology. 2012; 142: 622-310. FI: 11.675 (Q1).

Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, Spanish DILI Registry, Int Serious Adverse Events Consort. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.

Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB.

Pharmacogenet. Genomics. 2012; 22: 784-795. FI: 3.485 (Q1).

MicroRNAs in biliary diseases.

Muñoz-Garrido P, García-Fernández de Barrena M, Hijona E, Carracedo M, Marín JJG, Bujanda L, Bañales JM.

World J. Gastroenterol. 2012; 18: 6189-6196. FI: 2.471 (Q2).

Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models.

Hijona E, Bañales J, Hijona L, Medina JF, Arenas J, Herreros-Villanueva M, Aldazabal P, Bujanda L

Cancer Cell Int. 2012; 12: -0. FI: 1.973 (Q3).

Quantification of iron concentration in the liver by MRI.

Alústiza-Echeverría JM, Castiella A, Emparanza JI.

Insights Imaging. 2012; 3: 173-180. FI: 0.000 (Q0).

Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis.

Bañales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, Tietz Bogert PS, Bujanda L, Prieto J, Medina JF, LaRusso NF.

Hepatology. 2012; 56: 687-697. FI: 11.665 (Q1).